Creating affordable malaria vaccine proteins using E. coli
E. coli platform for expression of low-cost malaria fusion proteins
['FUNDING_SBIR_1'] · FINA BIOSOLUTIONS, LLC · NIH-10819079
This study is working on a new, affordable way to make proteins for malaria vaccines using a special type of E. coli, with the hope of helping protect young children under five who are most at risk for malaria.
Quick facts
| Phase | ['FUNDING_SBIR_1'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FINA BIOSOLUTIONS, LLC (nih funded) |
| Locations | 1 site (ROCKVILLE, UNITED STATES) |
| Trial ID | NIH-10819079 on ClinicalTrials.gov |
What this research studies
This research focuses on developing a low-cost method for producing malaria vaccine proteins using a specially engineered strain of E. coli. The goal is to make these proteins more accessible and effective for vaccine development, particularly for children under five who are most at risk of malaria. By utilizing a unique bacterial system, the researchers aim to produce these proteins in high yields while ensuring they are correctly folded and functional. Collaborations with leading institutions enhance the credibility and potential impact of this work.
Who could benefit from this research
Good fit: Ideal candidates for this research are children under the age of five living in malaria-endemic regions.
Not a fit: Patients who are not affected by malaria or are outside the target age group may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more affordable and effective malaria vaccines, significantly reducing malaria-related deaths, especially in young children.
How similar studies have performed: Previous research has shown promise in using bacterial systems for protein expression, but this specific approach is innovative and aims to address significant challenges in malaria vaccine development.
Where this research is happening
ROCKVILLE, UNITED STATES
- FINA BIOSOLUTIONS, LLC — ROCKVILLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: LEES, ANDREW — FINA BIOSOLUTIONS, LLC
- Study coordinator: LEES, ANDREW
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.